BACKGROUND: Inotuzumab ozogamicin (InO) has demonstrated efficacy and tolerability in patients aged 18 to 78 years with relapsed/refractory acute lymphoblastic leukemia (ALL) in the INO-VATE trial. This subset analysis compared the efficacy and safety of InO in younger and older patients. METHODS: Intent-to-treat analyses of morphologic responses and overall survival (OS) included 326 randomized patients, and safety assessments included 307 patients receiving 1 or more doses of the study treatment. Of the 326 patients, 164 received InO at a starting dose of 1.8 mg/m 2 /cycle (0.8 mg/m 2 on day 1 and 0.5 mg/m 2 on days 8 and 15 of a 21-to 28-day cycle [6 cycles]); 60 patients were aged 55 years, and 104 were aged <55 years. RESULTS: For older and younger patients, the median duration of InO therapy and the types and frequencies of adverse events of any grade were generally similar. Although the remission rates, median duration of remission (DOR), and progression-free survival were similar with InO for those aged <55 years and those aged 55 years, OS was longer for younger patients (median, 8.6 vs 5.6 months; hazard ratio, 0.610). Among patients proceeding to hematopoietic stem cell transplantation after InO treatment (28% of older patients and 58% of younger patients), the incidence of veno-occlusive disease was greater in older patients (41% vs 17%). The study database was not locked at the time of this analysis. CONCLUSIONS: InO was tolerable in older patients with relapsed/refractory ALL. Although OS was longer for younger patients versus older patients, InO demonstrated high response rates with similar DOR in the 2 age groups. Cancer 2018;124:1722-32.
INTRODUCTION
The last decade has seen remarkable advances in our understanding of the biological mechanism of acute lymphoblastic leukemia (ALL), and this has led to the development of novel therapeutic options that target specific patient subsets. The 5-year survival rate is approximately 50% to 70% for newly diagnosed younger adults with precursor B-cell ALL. 1, 2 In contrast, outcomes for older patients with ALL remain poor; induction mortality is considerable, and the 5-year survival rate is only 15% to 20%. 3, 4 Older patients are less likely to be suitable candidates for potentially curative hematopoietic stem cell transplantation (HSCT) because of comorbidities and a higher risk for complications that increase morbidity and mortality. 5 Maintaining treatment efficacy and preventing early mortality are major challenges in treating older patients with ALL. 3 Inotuzumab ozogamicin (InO) comprises a CD22 monoclonal antibody covalently linked to the potent cytotoxic agent calicheamicin. 6 InO has shown activity in adults with relapsed/refractory ALL, 7, 8 including those in a global, openlabel, phase 3, randomized trial (INO-VATE). 9 The aims of the current post hoc analysis were to evaluate InO efficacy and safety in older patients versus younger patients and to compare InO with standard therapy (ST) in INO-VATE trial patients.
MATERIALS AND METHODS
Details of the INO-VATE trial have been published previously. 9 The protocol was approved by the independent ethics committee or the institutional review board at each study center; the study was conducted in compliance with the ethical principles of the Declaration of Helsinki. Written informed consent was provided before any study procedures were conducted.
Trial Design, Patients, and Treatments
Briefly, for this global (19-country) , open-label, randomized trial, patients aged 18 years who had relapsed/ refractory (5% bone marrow blasts), CD22-positive, and Philadelphia chromosome-positive (Ph1) or Philadelphia chromosome-negative (Ph2) B-cell ALL and were due to receive their first or second salvage therapy were eligible. 9 Patients were randomized (1:1) to receive either InO or the investigator's choice of ST; no crossover between groups was allowed (additional details are included in the online supporting information).
Outcomes
Study outcomes have been previously described. 9 Treatment-emergent adverse events (TEAEs) of any cause were defined as any investigator-reported event that occurred between the first dose and 42 days after the last dose, any treatment-related adverse events (AEs), and any cases of hepatic veno-occlusive disease (VOD) that occurred within 2 years after randomization, even VOD events occurring after follow-up stem cell transplantation.
In this study, per protocol, VOD was defined as the occurrence of 2 of the 3 following clinical criteria: 1) a total serum bilirubin level > 34 lmol/L (> 2.0 mg/dL), 2) an increase in the liver size from the baseline or the development of right upper quadrant pain of liver origin, and 3) a sudden weight gain > 2.5% due to fluid accumulation in the weeks following the infusion of the study medication or chemotherapy or HSCT conditioning/preparative therapy or the development of ascites not present at the baseline after such exposures and the absence of other explanations for these signs and symptoms. A second definition was the development of a bilirubin elevation, weight gain, or hepatomegaly plus histologic abnormalities on a liver biopsy demonstrating hepatocyte necrosis in zone 3 of the liver acinus, sinusoidal fibrosis, and centrilobular hemorrhage with or without fibrosis of the terminal hepatic venules. A portal pressure elevation > 10 mm Hg was also used in diagnosing VOD.
Statistical Analysis
The 2 primary endpoints were 1) the complete response (CR)/complete response with incomplete hematologic recovery (CRi) rate per the endpoint adjudication committee in the intent-to-treat (ITT) population for the initial population of 218 randomized patients and 2) the overall survival (OS) in the ITT population (the 1-sided a value of .025 was evenly split between the 2 primary endpoints). Selected secondary endpoints included the following: safety measures, duration of remission (DOR), progression-free survival (PFS), subsequent HSCT rate, and minimal residual disease (MRD)-negativity rate (definitions appear in the online supporting information).
Herein we report results stratified by the age at randomization (55 vs <55 years [plus an additional analysis of patients aged 18 to 29 years and patients aged 30 to 54 years]). Binomial exact 95% confidence intervals (CIs) were provided for response and HSCT rates.
RESULTS

Patients and Treatment
Between August 27, 2012, and January 4, 2015, 326 patients (InO, 164; ST, 162) were randomized (the ITT population); 307 patients (InO, 164; ST, 143) received 1 or more doses of the assigned regimen (the safety population). In both the InO and ST arms, the baseline demographics and disease characteristics were generally similar for younger patients (aged <55 years) and older patients (aged 55 years), although a Ph 1 karyotype and an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 2 were more frequent in older patients (Table 1) . Additional information is included in the online supporting information and Supporting Table 1 .
Outcome
Response and HSCT rate
In the overall population (cutoff date, March 8, 2016) , the CR/CRi rate according to the investigator's assessment in the ITT population was higher with InO versus ST (73% vs 31%; 1-sided P < .0001). With InO, CR/ CRi rates were similar in patients aged 55 years and patients aged <55 years (70% vs 75%, respectively; 1-sided P 5 .24). In older patients, a higher proportion of patients achieved CRi (43%) versus CR (27%; Table 2 ). Among InO responders, the MRD-negativity rate was similar among older and younger patients (79% and 76%, respectively; P 5 .64). Similarly, no significant differences in response rates or MRD-negativity rates were observed between older and younger patients with ST. The CR/CRi rates were significantly higher with InO versus ST in both age groups (1-sided P < .0001).
In the safety population, more patients in both the younger and older cohorts proceeded to HSCT after study treatment and before any postinduction therapy with InO versus ST (younger patients, 53% With InO, significantly more younger patients in the safety population proceeded to HSCT before postinduction therapy in comparison with older patients (53% vs 27%; rate difference, 26%; 95% CI, 12%-41%; 1-sided P 5 .0008). Of these patients, 44% (7 of 16) in the older group and 75% (41 of 55) in the younger group received a myeloablative conditioning regimen. Twenty patients (19%) in the younger group and 9 (15%) in the older group who were treated with InO had undergone HSCT before the study; 60 patients (58%) in the younger group and 17 (28%) in the older group underwent HSCT at any time after the study. In patients treated with ST, the difference in the HSCT rates of the 2 age groups was not significant. Additional results for patients aged 18 to 29 years and patients aged 30 to 54 years are presented in the online supporting information. 
PFS
With InO, PFS was not significantly different between older patients (median, 4.9 months; 95% CI, 3.4-5.7 months) and younger patients (median, 5.0 months; 95% CI, 3.7-6.0 months) in the ITT population (HR for younger patients vs older patients, 0.795; 1-sided P 5 .1010; Table 3 and Fig. 1 ). PFS was longer with InO versus ST in patients aged <55 years (median, 5.0 vs 1.6 months; HR, 0.433; 1-sided P < .0001) and in patients aged 55 years (median, 4.9 vs 2.0 months; HR, 0.528; 1-sided P 5 .0006). Similarly, among older patients aged 65 years, PFS was longer with InO versus ST (median, 5.1 vs 3.1 months; HR, 0.448; 1-sided P 5 .0088).
OS
With InO, OS was longer for younger adults (median, 8.6 months; 95% CI, 7.0-11.1 months) versus older adults (median, 5.6 months; 95% CI, 4.8-8.0 months; HR, 0.610; 1-sided P 5 .0032; Table 3 and Fig. 2) . OS was longer with InO versus ST for patients aged <55 years (median, 8.6 vs 8.0 months; HR, 0.680; 1-sided P 5 .0092) but was not significantly different from ST for patients aged 55 years (median, 5.6 vs 5.3 months; HR, 0.903; 1-sided P 5 .3024; Fig. 3) . A landmark analysis (excluding patients with OS < 45 days) of patients receiving InO and achieving CR/CRi indicated that patients with follow-up HSCT had longer OS than patients without follow-up HSCT (median, 11.9 vs 5.7 months; HR, 0.477; P 5 .0004).
Among younger patients receiving InO, the median OS was 11.1 months for those aged 18 to 29 years and 7.7 months for those aged 30 to 54 years (Fig. 3) . In patients aged 18 to 29 years, OS was longer with InO versus ST (median, 11.1 vs 9.1 months; HR, 0.528; 1-sided 
Transplant-related outcomes
Sixty younger patients (58%) and 17 older patients (28%) proceeded to poststudy HSCT after InO treatment: 10 of the 60 patients (17%) aged <55 years (including 5 with prestudy HSCT) and 7 of the 17 patients (41%) aged 55 years (none with prestudy HSCT) experienced VOD after poststudy HSCT. One of these patients in each age group experienced VOD after HSCT after follow-up systemic induction therapy. The mortality rate among patients receiving InO with follow-up HSCT was lower for younger patients (57% [34 of 60]) versus older patients (71% [12 of 17] ). With InO, VOD was the cause of death for 12% of deaths (4 of 34) among younger patients and for 8% of deaths (1 of 12) among older patients; 40% of the younger patients (4 of 10) developing posttransplant VOD died because of VOD, whereas 14% of the older patients (1 of 7) died because of VOD.
Additional HSCT results for patients with Ph1 ALL versus Ph2 ALL by age are presented in Supporting Table 4 (see online supporting information).
Safety
With InO, the frequencies of TEAEs of any grade and grade 3 or higher TEAEs were generally similar for older and younger patients in the safety population (any grade, 100% for older patients and 99% for younger patients; grade 3 or higher, 98% for older patients and 87% for younger patients). Grade 3 or higher TEAEs that were more commonly reported in the older population than the younger population (difference in frequency 10%) included thrombocytopenia (57% vs 32%), febrile neutropenia (35% vs 22%), and c-glutamyltransferase elevations (18% vs 7%). Grade 3 or higher treatmentemergent infections were more common in older patients than younger patients receiving InO (37% vs 24%). Grade 5 TEAEs were similar between older and younger patients receiving InO (18% vs 14%).
Older and younger patients generally had similar types and incidences of AEs of any grade within each treatment arm and between arms (Table 4) . Similarly, within treatment arms, patients aged 18 to 29 years generally experienced types and incidences of AEs similar to those experienced by patients aged 30 to 54 years (Supporting Table 5 [see online supporting information]).
With InO, hepatobiliary TEAEs were reported in 37% of older patients (grade 3 or higher, 17%) and in 31% of younger patients (grade 3 or higher, 16%). VOD was reported as a TEAE in 15% of older patients (grade 1, 0%; grade 2, 3%; grade 3, 7%; grade 4, 3%; and grade 5, 2%) and in 13% of younger patients (grade 1, 1%; grade 2, 1%; grade 3, 3%; grade 4, 4%; and grade 5, 4%). Among the patients who proceeded to HSCT, 10 patients (17%) aged <55 years and 7 patients (41%) aged 55 years developed VOD after poststudy HSCT. A total of 3 patients (3%) aged <55 years and 2 patients (3%) aged 55 years experienced VOD during or shortly after treatment before any poststudy HSCT; of these patients, 2 and 0, respectively, had undergone HSCT before the study. Among all patients who received InO and proceeded to HSCT, the median time to VOD was 15 days (range, 3-57 days). Additional safety results are presented in the online supporting information including Supporting Table 6 . Decreased appetite  11  1  13  2  10  2  17  2  Pain in extremity  11  0  3  0  14  1  0  0  Back pain  9  4  15  2  10  1  2  0  Asthenia  9  2  10  3  5  0  17  4  Hypotension  9  0  5  2  1 6  3  1 7  6  Lipase increase  9  5  10  3  0  0  2  2  Upper abdominal pain  9  1  5  0  1 3  0  0  0  Rash  8  0  10  0  20  0  17  0  Pain  7  2  10  2  5  2  6  2  Dizziness  7  0  8  0  1 2  0  1 0  0  Peripheral edema  6  0  12  2  8  0  12  0  Hyperglycemia  6  1  12  3  8  4  10  6  Mucosal inflammation  5  1  2  0  1 4  1  1 3  4  Arthralgia  4  1  10  0  5  0  4  0  Dyspnea  4  0  10  3  14  2  10  2  Hypocalcemia  4  2  12  2  11  4  10  2  Hypomagnesemia  4  0  10  0  11  1  4  0  Fall  4  0  13  0  2  0  4  0  Hypophosphatemia  3  1  10  7  10  7  2  0  Amylase increase  2  1  10  3  0  0  2  0  Pruritus  2  0  10  0  9  0  4  0  Confusional state  0  0  2  0  1  0  1 2  2  Infections  46  24  53  37  76  52  79  62  Pneumonia  11  8  3  3  7  4  1 2  4  Hepatic adverse events  AST increase  20  6  27  2  11  4  12  2  ALT increase  17  4  12  3  14  5  10  4  GGT increase  16  7  30  18  10  4  6  6  Hyperbilirubinemia  20  7  23  5  18  7  15  6  VOD  13  11  15  12  1  1  0  0  ALP increase  9  2  22  2  8  0  6  0 Abbreviations: ALP, blood alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, g-glutamyltransferase; VOD, venoocclusive disease.
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DISCUSSION
Age is a major determinant of prognosis for adult ALL, and multiple studies have shown that older patients have significantly worse outcomes. 3, 4 Historically, older patients experience higher relapse and mortality rates than younger patients, 3 with a 5-year survival rate of 17% for older patients (aged 60 years) versus 51% for younger patients (aged <40 years). 10 The reasons for the poor prognosis associated with older age are multifactorial and include more extensive comorbidities, more aggressive disease characteristics (eg, a higher frequency of Ph1 and t(4;11) disease), poor tolerance of intensive chemotherapy, high mortality during inductionconsolidation-maintenance phases of therapy, patient ineligibility for or refusal to undergo potentially curative HSCT, and high HSCT-related mortality.
3 Despite progress in supportive-care measures and the use of lowintensity chemotherapy regimens, induction mortality rates as high as 42% have been reported for older patients, 3 and they are largely due to infections and a higher rate of end-organ toxicities resulting from the increased number and severity of comorbid conditions.
As expected in the INO-VATE trial, the percentage of patients with Ph1 ALL receiving InO was higher in the 55-year age group than the <55-year age group (23% vs 8%); older patients receiving InO also had a worse ECOG PS at the baseline (18% of the older patients and 10% of the younger patients had an ECOG PS of 2). Although responses to the first induction regimen were similar for older and younger patients receiving InO (82% vs 84%, respectively), the median duration of first remission was shorter for older patients (9 vs 12 months), and the percentage of patients who achieved CR with the most recent induction treatment before randomization was higher in the younger population (77% vs 68%). In addition, lower CD22 expression was more common among older patients. Despite this, no significant differences in remission rates were observed between age groups in either arm.
In this post hoc analysis, response rates, MRDnegativity rates, DOR, and PFS were similar between InOtreated patients aged <55 years and those aged 55 years. CR/CRi rates were significantly higher and PFS and DOR were significantly longer with InO versus ST in both younger and older patients (1-sided P .04). MRD-negativity rates among responders were significantly higher with InO versus ST in patients aged 30 to 54 years and patients aged 55 years (1-sided P .0023). Response rates also were higher in older Ph1 patients with InO versus ST.
Older patients with ALL generally have higher TEAE rates and may be recommended for experimental therapies after fewer prior treatment options. 11 In our study, older and younger patients had similar salvage statuses and had similar incidences of TEAEs of any grade (100% vs 99%, respectively) and grade 3 or higher TEAEs (98% vs 86.5%) with InO; however, certain TEAEs, including thrombocytopenia, febrile neutropenia, and cglutamyltransferase increases, occurred more frequently (by 10%) in the older population. In both age groups, most AEs were hematologic in nature.
Liver toxicities and VOD are known to occur with InO treatment. [7] [8] [9] A prespecified safety analysis of data from the INO-VATE trial reported that there are 2 significant covariables predicting the risk of VOD: an age 55 years from a univariate analysis (odds ratio for 55 vs <55 years, 3.500; 95% CI, 1.075-11.398; P 5 .04) and a dual-alkylator conditioning regimen (odds ratio for a dual regimen vs a single regimen, 8.606; 95% CI, 1.516-48.861; P 5 .02). 12 In this post hoc analysis, the frequencies of hepatic toxicities during InO therapy were similar for younger and older patients. With InO, VOD occurred more frequently in older patients who proceeded to HSCT after study therapy (7% of patients aged 18-29 years, 24% of patients aged 30-54 years, and 41% of patients aged 55 years).
Allogeneic HSCT is considered the only potentially curative treatment option for relapsed ALL. [13] [14] [15] However, HSCT is less well tolerated in older patients versus younger patients, and this results in higher mortality. 3, 4, 13 Because of this, myeloablative HSCT (ie, full-intensity conditioning) is not recommended for older patients. 3 In the INO-VATE study and in line with previous reports, fewer older patients versus younger patients proceeded to HSCT after the study with InO (28% vs 58%). With InO, older patients proceeding to HSCT had a higher incidence of VOD in comparison with younger patients (41% of patients aged 55 years vs 17% of patients aged <55 years [2-sided P 5 .0315] and 7% of patients aged 18-29 years). Conditioning regimens may have also contributed to the risk of VOD because the use of a dualalkylator conditioning regimen versus a single-alkylator conditioning regimen is associated with the occurrence of VOD after InO therapy. [7] [8] [9] 12 In the current study, more older patients than younger patients (56% vs 25%) in the InO group received a reduced-intensity conditioning regimen; this might have contributed to the lower mortality rate due to posttransplant VOD observed in the older patients versus the younger patients (14% vs 40%). The improvement of outcomes for patients treated with InO followed by HSCT may be optimized by the use of reduced-intensity conditioning regimens and VOD preventive and/or therapeutic measures (eg, ursodiol and defibrotide). 9, [16] [17] [18] In the current study, both younger and older patients demonstrated improvements in OS with InO versus ST; however, the OS benefit was not statistically significant among older patients. The difference in the OS benefit between younger and older patients could be due to the higher rate of younger patients proceeding to poststudy HSCT with InO versus older patients (58% vs 28%) because both younger and older patients who underwent follow-up HSCT had better OS outcomes than patients who did not undergo follow-up HSCT.
Although response rates, MRD-negativity rates, DOR, and PFS were similar with InO between those aged <55 years and those aged 55 years, OS was significantly longer for younger patients than older patients. This may be due to the higher percentage of younger patients versus older patients who proceeded to HSCT after the first InO dose until the start of postinduction therapy (53% vs 27%). Patients who underwent follow-up HSCT after InO treatment had significantly better landmark OS outcomes (measured with 45 days after randomization as the start date) than those who did not. Therefore, minimizing VOD risk by limiting the number of InO cycles, avoiding dual-alkylator conditioning regimens, and closely monitoring bilirubin levels before and during treatment may improve long-term outcomes in patients, especially older patients, receiving InO. 12 In addition, in older patients with relapsed/refractory ALL who may not be candidates for HSCT, InO is currently being studied and could potentially be beneficial in combination with maintenance therapy (ClinicalTrials.gov identifier NCT01925131).
In summary, our analysis supports the continued evaluation of InO as the first or second salvage treatment for older adults with relapsed/refractory ALL, a population with a poor prognosis and limited treatment options. Lower doses of InO and its combination with lowintensity chemotherapy regimens are being evaluated. 19 
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